Company intelligence / Profile preview

Emerald Health Pharmaceuticals Inc.

San Diego, California, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

EHP developed novel cannabinoid-derived therapeutics for neurodegenerative, autoimmune, inflammatory, and fibrotic diseases. Their lead candidate EHP-101 received Fast Track designation from the FDA for systemic sclerosis and was advancing to Phase 2 clinical trials for both systemic sclerosis and multiple sclerosis. The company was acquired by Skye Bioscience in 2022.

Therapeutic areas: NeurologyRheumatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

etrinabdione

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Emerald Health Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emerald Health Pharmaceuticals Inc..

Explore the full profile